Drugs / MK-4830
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06413095 | Jun 2022 → Jun 2023 | head and neck squamous cell carcinoma, soft tissue sarcoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03564691 | Jul 2018 → Sep 2025 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT05319730 | May 2023 → Jun 2027 expected | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05342636 | Jul 2022 → Dec 2025 | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04938817 | Aug 2021 → Dec 2029 expected | small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04626518 | Dec 2020 → Jul 2026 overdue | clear cell renal carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04303169 | Jun 2020 → Sep 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04165070 | Dec 2019 → Feb 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05446870 | Jul 2022 → Dec 2023 | ovarian serous adenocarcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04924101 | Jul 2021 → Jun 2025 | small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04895722 | Jun 2021 → May 2025 overdue | colorectal cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04165096 | Jan 2020 → Apr 2025 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04165083 | Dec 2019 → Oct 2025 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4830 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05342636 ↗ |
| Action | Inhibit | “First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism” PMID 34598945 ↗ Oct 2021 |
| Route | Intravenous | “MK-4830 will be administered intravenously (IV) Q3W.” NCT03564691 ↗ |